<DOC>
	<DOCNO>NCT02869061</DOCNO>
	<brief_summary>Autologous adipose-derived regenerative cell ( ADRC ) extract lipoaspirate enzymatic digestion portion fat harvest patient 's front abdominal wall . Transurethral bladder neck resection follow injection ADRCs suspension perform . This single arm study control . All patient receive cell therapy .</brief_summary>
	<brief_title>Effectiveness Safety Adipose-derived Regenerative Cells Reduction Risk Bladder Neck Contracture</brief_title>
	<detailed_description>Fat tissue obtainment : Subjects undergo liposuction local anesthesia . In procedure , Ringer 's solution anesthetic lidocaine vasoconstrictor adrenaline infuse adipose compartment minimize blood loss contamination tissue peripheral blood cell . 15 minute later hollow blunt-tipped 3 mm cannula introduce subcutaneous space small ( 0.5 cm ) incision . The cannula attach syringe gentle suction move adipose compartment , mechanically disrupt fat tissue . Aspirate volume - approximately 150-200 cc . Procedure time - 30 minute . ADRC isolation : Harvested adipose tissue process accord patent pending technology base enzymatic digestion , wash concentration cell pellet 9.5 ml normal saline.Obtained ADRC divide 2 portion . First portion ( 0.5 mL ) use counting , viability sterility assessment . The second portion ( 9 ml ) place sterile syringe injection . Surgery : Transurethral endoscopic loop resection bladder neck perform . Autologous ADRC administration : Injection ADRC suspension perform immediately bladder neck resection . 9 18 injection ( 0.5 1.0 mL ) inject endoscopic needle bladder neck close site resection . All injection perform single procedure .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Urinary Bladder Neck Obstruction</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<criteria>Bladder neck contracture transurethral prostate resection . Obstructive pattern urine flow rate maximum flow rate 15 mL/s Patient familiar Participant information sheet Patient sign informed consent form Noninclusion Criteria : Contraindications spinal , epidural inhalation anesthesia Urethral stricture Genitourinary inflammatory disease Prostatespecific antigen ( PSA ) level 4 ng/mL Contraindications local anesthesia history allergy local anesthetic Systemic glucocorticoid and/or immunosuppressant therapy Any condition might limit compliance ( dementia , mental disorder , narcotic drug alcohol abuse etc . ) Participation clinical trial ( administration investigational drug ) 3 month prior inclusion Patients malignant tumor include postoperative period , patient receive chemotherapy and/or radiotherapy Clinically significant abnormality result laboratory test Patient receive anticoagulant least 12 hour prior liposuction Medical history heterotopic ossification Patients prescribed glycoprotein inhibitor treatment Patient 's refusal participation trial Chronic kidney disease IV V stage ( creatinine clearance &lt; 30 mL/min estimate CockcroftGault formula ) Confirmed syphilis , HIV , hepatitis B C infection</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bladder neck obstruction</keyword>
	<keyword>Bladder outlet obstruction</keyword>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>Urinary bladder neck obstruction</keyword>
	<keyword>Bladder neck contracture</keyword>
	<keyword>Bladder neck stricture</keyword>
	<keyword>Bladder neck stenosis</keyword>
	<keyword>Transurethral resection prostate</keyword>
	<keyword>Prostatectomy</keyword>
	<keyword>Stromal vascular fraction ( SVF )</keyword>
	<keyword>Adipose-derived regenerative cell ( ADRC )</keyword>
	<keyword>Adipose tissue</keyword>
	<keyword>Stem cell</keyword>
</DOC>